Nivolumab plus ipilimumab in melanoma brain metastases
- PMID: 35114122
- DOI: 10.1016/S1470-2045(22)00001-8
Nivolumab plus ipilimumab in melanoma brain metastases
Conflict of interest statement
AMDG has served as a consultant or advisor to Incyte, Pierre Fabre, GlaxoSmithKline, Bristol-Myers Squibb, Merck Sharp Dohme, and Sanofi and has received compensated educational activities from Bristol-Myers Squibb, Merck Sharp Dohme, Pierre Fabre, and Sanofi. MM has served as a consultant or advisor to Roche, Bristol-Myers Squibb, Merck Sharp Dohme, Incyte, AstraZeneca, Amgen, Pierre Fabre, Eli Lilly, GlaxSmithKline, Sciclone, Sanofi, Alfasigma, and Merck Serono and own shares in Epigen Therapeutics.
Comment in
-
Nivolumab plus ipilimumab in melanoma brain metastases.Lancet Oncol. 2022 Feb;23(2):e52. doi: 10.1016/S1470-2045(22)00010-9. Lancet Oncol. 2022. PMID: 35114121 No abstract available.
Comment on
-
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.Lancet Oncol. 2021 Dec;22(12):1692-1704. doi: 10.1016/S1470-2045(21)00545-3. Epub 2021 Nov 10. Lancet Oncol. 2021. PMID: 34774225 Free PMC article. Clinical Trial.
-
Nivolumab plus ipilimumab in melanoma brain metastases - Authors' reply.Lancet Oncol. 2022 Feb;23(2):e54. doi: 10.1016/S1470-2045(22)00033-X. Lancet Oncol. 2022. PMID: 35114123 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
